PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 601: Translational reprogramming disrupts mitosis to drive SMAD4-deficient esophageal adenocarcinoma.

View Full Paper
JMJulia V. MilneKWKa Meng WuSWSasha Witts

Key Points

  • The aim is to investigate the role of SMAD4 in maintaining chromosomal stability in esophageal adenocarcinoma (EAC).
  • Employ multi-omics approaches including RNA-sequencing, proteomics, and reverse-phase protein array.
  • Use live cell imaging to observe mitotic errors in TP53-mutant SMAD4-deficient cells.
  • Analyze TCGA data for chromosomal instability prevalence in tumors with SMAD4 and TP53 mutations.
  • Perform biochemical analyses to assess translation mechanisms in cancer cells.
  • Conduct polysome sequencing to evaluate translation of mitotic proteins.
  • SMAD4-deficient cells showed significantly more mitotic errors, especially in chromosome segregation.
  • Chromosomal instability was more prevalent in tumors with both SMAD4 and TP53 mutations compared to individual mutations.
  • Increased cap-dependent translation was observed, while IRES-mediated translation decreased.
  • Decreased translation of a mitosis-specific cell cycle kinase was noted in SMAD4-deficient cells, without affecting transcription.
  • Ectopic expression of the mitosis-specific kinase rescued mitotic errors from SMAD4 loss.

Abstract

Abstract Esophageal adenocarcinoma (EAC) develops from a precursor lesion named Barrett’s esophagus; a progression that can be mapped by increasing genomic instability. We have previously shown that SMAD4 loss induces tumorigenesis and increased copy number alterations (CNA) in Barrett’s esophagus cells with an existing TP53 mutation. The observed CNA increase was especially pronounced in the resultant SMAD4-deficient tumor cells, suggesting that accumulation of mitotic errors occurs in these cells throughout their oncogenic progression. However, such an effect cannot be explained by our current understanding of canonical SMAD4 signalling. Thus, in this study, we aimed to delineate the role of SMAD4 in maintaining chromosomal stability in EAC. Our multi-omics (RNA-sequencing, proteomics and reverse-phase protein array) approach detected both deregulated translation and mitosis signatures in SMAD4-deficient cells. Using live cell imaging, we demonstrated that TP53-mutant SMAD4-deficient cells exhibit significantly more mitotic errors than TP53-mutant only cells, particularly chromosome segregation defects, which frequently result in chromosomal instability (CIN). Consistent with this, analysis of TCGA data demonstrated that CIN was more prevalent in tumours with both SMAD4 and TP53 mutation than either mutation alone. Further biochemical analyses revealed an increase in cap-dependent translation in these cells, and a decrease in internal ribosome entry site (IRES)-mediated translation. IRES-mediated translation is essential for synthesis of many important mitotic proteins, including a mitosis-specific isoform of a cell cycle kinase. Polysome sequencing showed decreased translation (but not transcription) of this kinase in SMAD4-deficient cells. Ectopic expression of mitosis-specific isoform of this kinase rescued the mitotic errors that arose as a consequence of SMAD4 loss. In sum, we present a model where translational reprogramming disrupts mitosis, inducing CIN and potentially driving EAC tumorigenesis in response to loss of SMAD4. This represents a novel mechanism of tumorigenesis in EAC and a previously unknown role of SMAD4 in maintaining chromosomal integrity. Citation Format: Julia V. Milne, Ka Meng Wu, Sasha Witts, Eric Kusnadi, Kenji Fujihara, Katherine Papastratos, Maree Pechlivanis, Anna Trigos, Metta Jana, Luc Furic, Kaylene Simpson, David Liu, Cuong Duong, Wayne Phillips, Nicholas Clemons. Translational reprogramming disrupts mitosis to drive SMAD4-deficient esophageal adenocarcinoma abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 601.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Milne et al. (2026) studied this question.

synapsesocial.com/papers/69d1fca7a79560c99a0a2469https://doi.org/10.1158/1538-7445.am2026-601
Ask AI
Helpful
Bookmark
Share
View Full Paper